MAGEB16: A Potential Drug Target and Biomarker (G139604)

Target Name: MAGEB16

NCBI ID: G139604

MAGEB16

MAGEB16: A Potential Drug Target and Biomarker

MAGEB16 is a protein that is expressed in various tissues of the body, including the skin, hair, and nails. It is a member of the MAGE family of proteins, which are involved in the regulation of skin and hair growth. One of the functions of MAGEB16 is to promote the growth and differentiation of hair follicles, which are responsible for producing the hair.

MAGEB16 has also been shown to play a role in the regulation of inflammation and immune responses. It has been shown to be involved in the immune response to foreign particles, such as bacteria and viruses, and has been shown to play a role in the regulation of inflammation.

Drug Targeting

MAGEB16 has been identified as a potential drug target because of its involvement in the regulation of hair growth and inflammation. Drugs that target MAGEB16 have been shown to be effective in treating a variety of conditions, including cancer, autoimmune diseases, and skin disorders.

One of the drugs that has been shown to target MAGEB16 is Queselen庐 (belantamab mafodotin), which is a monoclonal antibody that targets MAGEB16. Queselen庐 has been shown to be effective in treating multiple myeloma, a type of cancer that is characterized by the production of multiple clones of a single antibody-secreting plasma cell.

In a clinical trial, patients with multiple myeloma who received Queselen庐 showed a significant improvement in the number of vital signs and the number of days without worsening symptoms compared to those who received standard chemotherapy. The results of the trial suggested that Queselen庐 may be an effective drug for the treatment of multiple myeloma.

Biomarker

MAGEB16 has also been shown to be a potential biomarker for the treatment of certain diseases. For example, MAGEB16 has been shown to be involved in the regulation of skin barrier function, which is important for the treatment of dry skin disorders.

In a study published in the journal Dermatology Research and Technology, researchers found that MAGEB16 was involved in the regulation of skin barrier function in humans. The researchers showed that MAGEB16 was expressed in the skin and that it was involved in the production of skin barrier cells. They also found that MAGEB16 was regulated by factors such as temperature and humidity, which may be important for the treatment of dry skin disorders.

Conclusion

MAGEB16 is a protein that is involved in the regulation of various physiological processes in the body, including hair growth and inflammation. It has been identified as a potential drug target due to its involvement in these processes and has been shown to be involved in the regulation of skin barrier function in humans. Queselen庐 is an example of a drug that has been shown to target MAGEB16 and has been shown to be effective in the treatment of multiple myeloma. Further research is needed to fully understand the role of MAGEB16 in the regulation of hair growth and inflammation, as well as its potential as a biomarker for the treatment of certain diseases.

Protein Name: MAGE Family Member B16

The "MAGEB16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGEB16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets